CELH— AI Stock Forecast & Price Targets
Published 7/1/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live CELH price forecast →
CELH sits at $29.28, near 52-week lows ($27.47) and down ~36% YTD, but Q1 2026 shows a sharp operational reacceleration with revenue of $782.6M (+137% Y/Y post-Alani Nu) and net income of $110M. The setup is a classic beaten-down GARP/short-squeeze candidate — forward P/E 14.5x, PEG 0.77, 20.7% short float, analyst PT $59 — but the trailing P/E of 69x, elevated debt/equity of 1.95, and Q3 2025's net loss remind us execution is uneven and the model's own forecasts have consistently overshot realized prices.
1-4 weeks: accumulate on weakness toward $27.50-$28.50, with $27.00 as hard invalidation (breaks 52w low). Upside target $32-34 into potential earnings positioning (May 7 BMO next confirmed print, but the stock often runs into announcements). Size at 1/3 to 1/2 of a full position — the tape is choppy and the model's near-term bullish prob of 1.00 is contradicted by the model's own longer-term forecast rolling over. Take partial profits at $32; stop full stop if daily close below $27.00.
1-6 months: this is the confirmation window. If Q2 2026 sustains the Q1 run rate (revenue >$700M, operating margin >17%), the forward P/E of ~14x makes the stock a $40-45 name easily. If margins slip toward Q3 2025 levels, we retest $25. Expected return range -15% to +40% skewed slightly positive given the short float (20.7%, short ratio 4.2 — genuine squeeze fuel) and directors' recent buying reported in sentiment channels. Change my mind: sustained institutional selling (already -1.84% Inst Trans), a competitor gaining shelf space in convenience/mass, or another quarter of negative operating cash flow.
1-3 years: terminal thesis depends on whether CELH+Alani Nu+Rockstar can hold #2/#3 US energy drink share against Monster and Red Bull, and whether the international expansion delivers. TAM is real and category is growing, but private label and Ghost/Bang-type disruptors have shown category loyalty is fragile. If revenue compounds at even 15% off a $2.97B base and margins normalize at 18-20%, the business earns $2.50-3.00 EPS in 2028 — 12-15x that is $30-45, so at $29 the market is pricing in NO further multiple recovery. Biggest structural risk: category deceleration ('management's own guidance' per UBS) becoming secular, not cyclical, combined with debt/equity of 1.95 limiting balance-sheet flexibility in a downturn.
The quarterly income statement tells a two-part story: Q1 2026 revenue of $782.6M is roughly 6x the pre-Alani Nu run rate, with gross margin of 48.3%, operating margin 18.3%, and net income of $110M — a clean, profitable print. But look at Q3 2025 ($725M revenue with a $61M net LOSS and negative EBITDA) — the trajectory is not linear, and integration charges/one-timers have distorted TTM EPS to just $0.43, driving the 69x trailing P/E. Forward P/E of 14.5x and PEG 0.77 look attractive if the Q1 run rate holds. Balance sheet is workable but stretched: $549M cash against $676M debt, debt/equity 1.95, LT debt/eq 1.94; current ratio 1.73 is adequate. Cash flow is lumpy — Q1 2026 FCF of $65.8M is fine, but Q4 2025 posted -$130M operating cash flow. Gross margin trend (47-51%) shows the beverage business is structurally healthy; the question is whether the Alani Nu synergies stick. UBS trimming PT to $50 but keeping Buy is consistent with 'good asset, wait for confirmation.'
Across timeframes the price sits deep in a multi-quarter downtrend: the weekly chart shows the collapse from ~$95 highs to current $29.28 has stabilized in a $27.47-$31.50 base since April/May 2026, and price is now testing the upper half of that range. SMA200 is -33% overhead, SMA50 -4.6%, SMA20 +0.7% — a classic early-basing pattern where short-term MAs are converging. RSI 47.5 is neutral, giving room in either direction. The 1h and 4h forecasts project mean-reversion toward $36-53, but the 1d model forecast has actually rolled OVER (yellow line drifting from ~$46 back to $37.9 by late October), which is a warning that the algo sees the bounce as tactical, not structural. Directional accuracy is only 61% at 1d vs a 59% naive baseline — barely better than a coin flip — and MAPE of 39% is enormous. Key levels: support $27.47 (52w low) and $28.00; resistance at the $31.50 swing high, then the $34-36 gap zone, then $40 (200-day area is much higher). Bullish divergence isn't confirmed until the stock reclaims $32 on volume.
Signal: two major analysts — UBS ($50, from $55) and Roth ($57, from $65) — cut price targets in late June while maintaining Buy ratings, and UBS specifically flagged 'core business deceleration in line with management,' which is a lukewarm defense. Simply Wall St. also trimmed fair value from $61.35 to $58.52. The consistent theme is 'targets coming down but still well above current price' — analysts are hedging without capitulating. J.P. Morgan reportedly still has CELH as a 2026 top pick, but the piece notes the stock has meaningfully lagged the other two picks at the halftime mark. Noise: standard daily-close recaps. Net-net, the sell-side is trimming, not abandoning, and there are no acute negative catalysts — the risk here is a slow bleed on expectations rather than a shock.
- Alani Nu integration synergies — Q1 2026 revenue +137% Y/Y evidences successful revenue capture; next milestone is proving cost synergies via sustained 18%+ operating margin
- International expansion (Europe, APAC) explicitly listed in company description — still early-innings and mostly optionality at current valuation
- New product extensions: CELSIUS ESSENTIALS (aminos) and CELSIUS Hydration powder/sticks broaden the platform beyond RTD energy
- Short squeeze catalyst — 20.7% short float and 4.2 short ratio, up +3.4pp in 45 days, combined with any earnings beat could trigger a mechanical rally
- Insider ownership of 28.75% and reported recent director buying signal management alignment
- Trailing P/E of 69x is unforgiving — any Q2 disappointment on the Q1 reacceleration rerates the stock lower fast
- Debt/equity of 1.95 and $676M total debt limit flexibility; Q4 2025 posted -$130M operating cash flow showing lumpy cash generation
- Analyst PT cuts (UBS to $50, Roth to $57) and 'core business decelerating' commentary from UBS suggest sell-side is trimming expectations
- Short float rising from 17.3% → 20.7% in 45 days is a bearish positioning signal, not just squeeze fuel
- Q3 2025 net loss of $61M shows the business is not yet consistently profitable ex-Alani Nu contribution timing
- Sector risk: energy drink category growth is slowing per management commentary; category leaders (Monster) have far more balance sheet strength
- Forecast model reliability is weak — 1d directional accuracy just 61% vs 59% baseline, MAPE 39%, meaning forecast band is decorative not predictive at longer horizons
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord